IBRX ImmunityBio, Inc. Common Stock Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
16:12
Oct 14
wliang
IBRX ready for next leg up
Sees IBRX holding proper levels and ready for the next leg up; earlier said he remains bullish on the biotech theme for Q4 and IBRX should do well.
IBRX ImmunityBio, Inc. Common Stock Long — —
15:27
Oct 13
wliang
Bullish Q4 biotech theme includes IBRX
Remains bullish on the entire biotech theme for Q4 and says IBRX should do well.
IBRX ImmunityBio, Inc. Common Stock Long — —
17:09
Oct 12
wliang
IBRX strength expected in Q4
Expects Q4 biotech strength and sees IBRX strengthening throughout Q4, after its earlier-year move from ~$2 to ~$12.
IBRX ImmunityBio, Inc. Common Stock Long 1ST — —
Log in to see ideas

About IBRX Investor Commentary

Across the available history and selected sources, Buzzberg tracks IBRX (ImmunityBio, Inc. Common Stock) across 19 sources: 50 bullish vs 0 bearish calls from 38 authors. Historical directional balance: 54% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 93 total trade ideas tracked. Past 7 days, before deduplication: 2 other directions. Latest voices: wliang.